dillandinardo
Dillan DiNardo (@dillandinardo) focuses on neurotechnology, next‑generation psychoactive therapeutics, and clinical-data methodology. Covers regulatory signals, first‑in‑human claims, and measurement frameworks that could influence biotech and psychedelics catalysts.
Past bets that played out
Notable calls: a public post asserting completion of a first‑in‑human trial for a molecularly engineered ‘mental‑state’ platform framed as a sequel to psychedelics; and a separate post claiming FDA and EMA approval to begin human trials for a neurotech platform described as enabling “precision design” of altered states. Both claims require validation—no developer, trial details, endpoints, indication, or funding were provided in the posts.
A single social post claims completion of a first-in-human trial for a neurotech platform to “design mental states” at a molecular level, framing it as a sequel to psychedelics and a potential new class of psychoactive/mental-state therapeutics. No company name, trial details, indication, endpoints, regulator, or funding are provided, so the content is not directly tradable without identifying the developer and validating the claim.
A tweet claims the author’s organization received both FDA and EMA approval to begin human trials for a neurotech platform aimed at “precision design” of altered states (mood/cognition/perception), positioning it as beyond traditional psychedelics.
What this channel is watching now
Primary monitoring: EMA (ticker: EMA) flagged with higher conviction for regulatory signal coverage; HUM (ticker: HUM) tracked with lower conviction. Focus areas: validating developer identities, confirming trial registrations and regulatory filings, and assessing potential clinical endpoints and market implications if claims prove true.
Latest videos and market context
No recent video content available on file. Social posts and threads are the primary published material.
@nickcammarata @_StevenFan The first controlled double-blind clinical data on the next 5-MeO drops tomorrow...
Post hints at an imminent (tomorrow) release of the first controlled double-blind clinical data for a “next 5‑MeO” (5‑MeO‑DMT or related) psychedelic program. No company, indication, trial phase, or endpoint details are provided, so actionability is limited; however it suggests a near-term biotech/psychedelics catalyst that could move the most directly exposed public names.
@aourirabderahim Those are great points. We address those issues by cross-mapping the validated psychometrics with Me...
Discussion about improving measurement/labeling of psychoactive effects by cross-mapping validated psychometrics to MedDRA adverse events (AEs), plus an internal ontology and semantic embedding spaces. This is conceptual/product-methodology commentary (pharmacovigilance / clinical data / AI semantics) with no explicit company, catalyst, or security mentioned.
Pinned Dillan DiNardo @DillanDiNardo Sep 24, 2025 1/ It feels surreal to announce completion of the first human trial...
A single social post claims completion of a first-in-human trial for a neurotech platform to “design mental states” at a molecular level, framing it as a sequel to psychedelics and a potential new class of psychoactive/mental-state therapeutics. No company name, trial details, indication, endpoints, regulator, or funding are provided, so the content is not directly tradable without identifying the developer and validating the claim.
Dillan DiNardo @DillanDiNardo Sep 5, 2024 1/ We're thrilled to announce we've received both FDA & EMA approval to beg...
A tweet claims the author’s organization received both FDA and EMA approval to begin human trials for a neurotech platform aimed at “precision design” of altered states (mood/cognition/perception), positioning it as beyond traditional psychedelics.
Proof-backed call history
Recent activity includes threads and pinned posts that announce alleged regulatory approvals and first‑in‑human trial completions for a neurotech/psychedelics adjacent platform, commentary on imminent controlled psychedelic data releases, and methodological discussion about mapping psychometrics to MedDRA adverse events for better clinical measurement.
A tweet claims the author’s organization received both FDA and EMA approval to begin human trials for a neurotech platform aimed at “precision design” of altered states (mood/cognition/perception), positioning it as beyond traditional psychedelics.
A single social post claims completion of a first-in-human trial for a neurotech platform to “design mental states” at a molecular level, framing it as a sequel to psychedelics and a potential new class of psychoactive/mental-state therapeutics. No company name, trial details, indication, endpoints, regulator, or funding are provided, so the content is not directly tradable without identifying the developer and validating the claim.
About this channel
Analytical coverage centered on neurotech and next‑generation psychoactive therapeutics, with emphasis on regulatory catalysts, trial validation, and clinical‑data measurement. Reporting synthesizes social disclosures and technical commentary; assertions are presented with caveats when source details are incomplete.
@dillandinardo
Most recognized assets
Unlock the full track record
Follow @dillandinardo for timely threads on regulatory signals, trial claims, and clinical‑measurement methodology. Use posted claims as leads to verify filings, registries, and sponsor details before taking tradable action.